Facing the Challenges in Vaccine Upstream Bioprocessing - 23

W H I T E PA P E R

rAAV Production in Suspension
CAP GT® Cells in BioBLU®
3c and 10c Single-Use Vessels

Abstract

n pharmaceutical and biotech industry there
is an increasing interest in gene therapybased applications. This leads to an increasing
demand in scalable production systems for viral
vectors. Cell culture in suspension instead of
monolayer culture simplifies scale-up, because
it allows bioprocessing in scalable, stirred-tank

| GENengnews.com

bioreactors. Researchers at Cevec® Pharmaceuticals adapted a small scale shake flasks rAAV production process to stirred-tank bioreactors and
scaled it up in BioBLU Single-Use Vessels from a
working volume of 2 L to 10 L. Scale-up
in bioreactors was based on constant power
input/volume. It led to comparable cell growth
and virus production at both scales and to the
original shake flask process.

Introduction
Bioprocess development is usually carried out
at small working volumes. This helps saving time
and resources, because at small scale several

ADDITIONAL CONTENT
Bioreactor scalability is critical to streamlining
the adaptation of culture volumes during process
development and manufacturing. We discuss
different scaling approaches, underlined with two
case studies.
Watch webinar

4X-image/Getty Images

Simon Fradin1, Kerstin Hein1, and Helmut Kewes1
1Cevec Pharmaceuticals GmbH, Cologne, Germany
Robert Glaser2, Ulrike Rasche2, and Ma Sha3
2Eppendorf Bioprocess Center Juelich, Germany;
3Eppendorf Inc., Enfield, CT, USA

https://www.eppendorf.com/DE-de/service-support/eppendorf-training-center/webinars/recorded-webinars/recorded-webinar-cell-culture-scale-up-using-stirred-tank-single-use-bioreactors http://www.GENengnews.com

Facing the Challenges in Vaccine Upstream Bioprocessing

Table of Contents for the Digital Edition of Facing the Challenges in Vaccine Upstream Bioprocessing